CSF Biomarker Panel May Improve Diagnosis of CNS Lymphoma
TOPLINEA cerebrospinal fluid (CSF) biomarker panel, combining MYD88 mutation testing with interleukin 10 (IL-10) and C-X-C motif chemokine ligand 13 (CXCL13) measurements, showed high specificity for CNS lymphoma and correctly identified more than half of the CNS lymphoma cases. With further validation, this panel could help reduce reliance on invasive brain biopsy in selected patients, the authors suggested.METHODOLOGYBrain biopsy remains the reference standard for diagnosing primary CNS lymphoma but can be risky and contribute to diagnostic delays. CSF biomarkers, such as the MYD88 mutation, IL-10, and CXCL13, have shown promise in identifying CNS lymphoma, but most evidence has come from retrospective studies.
- ▪TOPLINEA cerebrospinal fluid (CSF) biomarker panel, combining MYD88 mutation testing with interleukin 10 (IL-10) and C-X-C motif chemokine ligand 13 (CXCL13) measurements, showed high specificity for CNS lymphoma and correctly identified mo
- ▪With further validation, this panel could help reduce reliance on invasive brain biopsy in selected patients, the authors suggested.METHODOLOGYBrain biopsy remains the reference standard for diagnosing primary CNS lymphoma but can be risky
- ▪CSF biomarkers, such as the MYD88 mutation, IL-10, and CXCL13, have shown promise in identifying CNS lymphoma, but most evidence has come from retrospective studies.
Medscape files mainly under health. We currently carry 231 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Medscape |
| Canonical URL | https://www.medscape.com/viewarticle/csf-biomarker-panel-may-improve-diagnosis-cns-lymphoma-2026a1000ok8?src=rss |
| Publication time | Tue, 21 Jul 2026 02:46:07 EDT |
| Retrieval time | 2026-07-21T07:07:04.087Z |
| Last seen | 2026-07-21T07:07:04.087Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | 97KKt6AINu4- |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
TOPLINEA cerebrospinal fluid (CSF) biomarker panel, combining MYD88 mutation testing with interleukin 10 (IL-10) and C-X-C motif chemokine ligand 13 (CXCL13) measurements, showed high specificity for CNS lymphoma and correctly identified more than half of the CNS lymphoma cases. With further validation, this panel could help reduce reliance on invasive brain biopsy in selected patients, the authors suggested.METHODOLOGYBrain biopsy remains the reference standard for diagnosing primary CNS lymphoma but can be risky and contribute to diagnostic delays. CSF biomarkers, such as the MYD88 mutation, IL-10, and CXCL13, have shown promise in identifying CNS lymphoma, but most evidence has come from retrospective studies.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
